Fu et al. (2020) also found that secretory OPN leads to acquired epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance by activating the integrin αVβ3/FAK pathway, which provides novel insights for the application of FAK inhibitors in lung cancer treatment. Here, PTK2 is linked to lung carcinoma.